The US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...

This insightful interactive webinar delves into the motor and non-motor symptoms experienced by patients with Parkinson’s ...

Parkinson's disease (PD) is the second most common neurodegenerative disorder, primarily characterized by motor dysfunction.

A 47-year-old man was the first in the world to be treated outside of a study context with a new technique for the symptoms ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Researchers have uncovered a new understanding of levodopa-induced dyskinesia, a common side effect in Parkinson’s patients, ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...

In the past, Parkinson’s disease was primarily considered a disorder of the nervous system, centered in the brain. However, ...

Learn how caffeine affects Parkinson's disease prevention and treatment. New research uncovers both protective benefits and treatment limitations.

University of Arizona researchers revealed that dyskinesia in Parkinson’s patients stems from a disconnect in the motor ...

offering a new therapeutic ... A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...